AHIP has released a new set of privacy principles that reaffirm the health insurance provider industry’s commitment to developing privacy, confidentiality, and cybersecurity practices to protect personal health information.
AHIP’s Board of Directors and its chief medical officers leadership team released core guiding priorities and a detailed roadmap to further protect the privacy, confidentiality, and cybersecurity of consumer health information. Health insurance providers have long been a leader in developing privacy, confidentiality, and cybersecurity practices to protect personal health information. These priorities reaffirm that commitment while offering a path forward for legislators and regulators to keep Americans’ health data secure and provide them with actionable health information.
“It is essential that every American is confident that their personal health information is private and protected—no matter who holds it,” said Matt Eyles, AHIP president and CEO. “Health insurance providers have long been committed to instituting privacy and cybersecurity practices to protect every individual’s personal health information – from employer-provided coverage to the individual market, from Medicare Advantage to Medicaid managed care. As new technologies emerge and the health care system continues to evolve, these priorities reaffirm AHIP and our members’ commitment to enhancing patients’ access to actionable health information while keeping their personal data secure. And by following the roadmap laid out by our industry’s leading experts, we believe that legislators and regulators can help give Americans the peace of mind they deserve.”
AHIP’s chief medical officers emphasized that new technologies—including telehealth, apps, and other digital health care services—should be subject to the Health Insurance Portability and Accountability Act (HIPAA) or similar requirements. They also advised that HIPAA and the Health Information Technology for Economic and Clinical Health Act and corresponding regulations should remain the primary legal framework for protecting Americans’ health information.
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More